Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 7804.016 | 1.0034 | 1.0030 | 2.3055 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 7804.016 | 1.0360 | 1.0309 | 2.3055 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 1.33 | uM | 7804.016 | 0.9921 | 0.9931 | 2.3055 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 6.67 | uM | 7804.016 | 0.8801 | 0.8922 | 2.3055 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 7804.016 | 0.6626 | 0.6730 | 2.3055 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7804.016 | 0.9081 | 0.9181 | 2.3055 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 9024.016 | 1.0893 | 1.0535 | 3.2430 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.00213 | uM | 9024.016 | 0.9861 | 0.9914 | 3.2430 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0107 | uM | 9024.016 | 1.0637 | 1.0385 | 3.2430 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 9024.016 | 1.0386 | 1.0235 | 3.2430 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 9024.016 | 1.0323 | 1.0197 | 3.2430 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 1.33 | uM | 9024.016 | 0.9297 | 0.9555 | 3.2430 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 6.67 | uM | 9024.016 | 0.9444 | 0.9651 | 3.2430 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 9024.016 | 0.8789 | 0.9220 | 3.2430 | ||
| BT-549 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 9024.016 | 0.8698 | 0.9158 | 3.2430 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 7805.016 | 1.0529 | 1.0873 | 1.2059 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.00213 | uM | 7805.016 | 0.9869 | 0.9782 | 1.2059 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0107 | uM | 7805.016 | 0.9685 | 0.9476 | 1.2059 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 7805.016 | 0.9005 | 0.8335 | 1.2059 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 7805.016 | 0.9530 | 0.9217 | 1.2059 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 1.33 | uM | 7805.016 | 0.9125 | 0.8538 | 1.2059 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 6.67 | uM | 7805.016 | 0.9665 | 0.9442 | 1.2059 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 7805.016 | 0.7355 | 0.5502 | 1.2059 | ||
| CAMA-1 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7805.016 | 0.0076 | -0.9650 | 1.2059 | ||
| HBL-100 | Unknown | Unknown | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 7807.016 | 0.9671 | 0.9691 | 2.1516 |